TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02525263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-Kidney Augment
Description: NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
Study: NCT04720547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: A nonbenzodiazepine hypnotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: A nonbenzodiazepine hypnotic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: The Control condition in which participants do not receive medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: The Control condition in which participants do not receive medication.
Study: NCT04800926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xavier wheelchair controller
Description: Controlling a wheelchair using the Xavier surface EMG system
Study: NCT03799224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBU/CY and ATG
Description: Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBU/CY
Description: hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
Study: NCT00193492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT01861990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: All participants enrolled on valproic acid arm.
Study: NCT04153825

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Current
Description: Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocollator hot-pack
Description: The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocollator hot-pack
Description: The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hydrocollator hot-pack
Description: The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hydrocollator hot-pack
Description: The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous Electrical Nerve Stimulation
Description: Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham interferential Current
Description: Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
Study: NCT04590196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Longvida curcumin
Description: longvida curcumin verdure sciences formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide
Study: NCT04346862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine hydrochloride 500mg
Description: The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
Study: NCT03496298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide (SAR439977)
Description: Pharmaceutical form: Solution for injection,~Route of administration: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide (SAR439977)
Description: Pharmaceutical form: Solution for injection,~Route of administration: SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: SC
Study: NCT03910361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
Study: NCT01169272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-SonR 9770
Description: Active implantable defibrillator with capacity of cardiac resynchronization therapy
Study: NCT02571530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Cerebral Infusion of Trastuzumab
Study: NCT04203667

Intervention type: DEVICE
Group type: OTHER
Intervention: EndoRotor Resection
Description: The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods.~The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter.
Study: NCT01841060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency ablation (RFA)
Description: Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
Study: NCT04153539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking along a busy road
Description: The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
Study: NCT05565755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Motivational interview Training
Study: NCT04153539

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking in a traffic-free park
Description: The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
Study: NCT00466531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT01625390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-6150
Description: Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptacog alfa [activated]
Description: comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
Study: NCT01352468

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Multifaceted cognitive training
Description: Four computerized training tasks
Study: NCT04471597

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: 5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
Study: NCT01625390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-6150
Description: Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
Study: NCT00918190

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron, Dexamethasone
Description: Use of ondansetron and dexamethasone as combined antiemetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, dexamethasone
Description: use of midazolam and dexamethasone as combined antiemetic
Study: NCT03163992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
Study: NCT02114827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: 23-minute video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAQ Sheet
Study: NCT00374621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol with or without isosorbide mononitrate
Description: Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol with or without isosorbide mononitrate
Description: Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
Study: NCT04596761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF-utilizing powered toothbrush
Description: RF-utilizing Powered toothbrush

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control placebo with no RF
Description: Placebo control, toothbrush with no RF
Study: NCT03753087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 10 mg tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care with no SGLT-2 inhibitors
Study: NCT00410384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Study: NCT02459340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic treatment (inpatient and outpatient setting)
Study: NCT01649726

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Apnea test - control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apnea test - CPAP
Study: NCT01096095

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Phenylbutyrate
Description: Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
Study: NCT04471597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
Study: NCT01192295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl controlled-release tablets
Description: Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
Study: NCT03547986

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Duplex Ultrasound (DUS)
Description: Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IVUS with Intraarterial pressure measurement (IAP) if needed
Description: Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
Study: NCT00461448

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium supplement
Description: Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium supplement
Description: Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
Study: NCT00630539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 5 mg
Description: 1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 15 mg
Description: 1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg
Description: 1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Study: NCT00618358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Sealant System
Description: The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam/Thrombin
Study: NCT02519179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opaque, weighted bottle
Description: This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear, conventional bottle
Description: This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
Study: NCT02250144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot orthoses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Foot orthoses
Study: NCT02668835

Intervention type: DEVICE
Intervention: Non intervention-Monitoring device
Description: Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.

Intervention type: DEVICE
Intervention: Non intervention-Monitoring device
Description: Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.

Intervention type: GENETIC
Intervention: Non intervention-Genetic testing

Intervention type: GENETIC
Intervention: Non intervention-Genetic testing
Study: NCT04127344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy Intervention
Description: Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
Study: NCT00696904

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, see arms for intervention description

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, see arms for intervention description

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, see arms for intervention description

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsule, see arms for intervention description

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsule, see arms for intervention description
Study: NCT02923895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: 0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: 0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
Study: NCT00647140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-L-DOPA PET
Description: PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
Study: NCT01072929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo, also in tablet form taken orally, once daily in the morning.
Study: NCT01008748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: NRT for participants who smoke \>10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Materials
Description: Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
Study: NCT04506190

Intervention type: PROCEDURE
Intervention: Revisional bariatric surgery
Description: Subjects who undergo revisional bariatric surgery
Study: NCT02759198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537
Description: Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Drug: Celecoxib 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YH23537 placebo
Description: Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo